Molecular diagnostics from Mobidiag
Mobidiag develops and markets molecular diagnostics for gastrointestinal infections, antimicrobial resistance management, healthcare-associated infections and respiratory infections (including COVID-19).
The company aims to provide a global solution to clinicians, suited for their own laboratory needs and capacities.
Following the COVID-19 crisis, Mobidiag has harnessed its existing technologies and expertise to develop and supply coronavirus molecular diagnostic tests. In addition to targeted tests for COVID-19, it is now offering RESP-4 multiplex panels, which are highly relevant to both the traditional influenza season and COVID-19.
Symptoms caused by most common winter season viruses (SARS-CoV-2, Influenza A, Influenza B and RSV) can be very similar, and it is imperative that healthcare professionals are able to distinguish between them rapidly, in order to start the appropriate treatment. Amplidiag RESP-4 (for batch testing) and Novodiag RESP-4 (for on-demand testing) are now available.
www.mobidiag.com
Other News
Featured Supplier
The British In Vitro Diagnostics Association represents the IVD Industry in the UK, to Government, professional bodies, the public, and at MedTech Europe. Giving support to members on regulatory issues, BIVDA also promotes the clinical and cost utility of IVDs in the provision of effective healthcare, both in acute diagnosis and in the prediction...
Upcoming Events
Lab Innovations 2021
NEC, Birmingham
3-4 November 2021
IBMS Biomedical Science Congress 2022
International Convention Centre, Birmingham
14-17 March 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store
